Table III.
Univariate analysis of the associations between clinical characteristics and COUP-TFII, LXR, RXRα, and SREBP-1c expression.
| COUP-TFII | LXR | RXRα | SREBP-1c | |||||
|---|---|---|---|---|---|---|---|---|
| Variable | Positive, n (%) | P-value | Positive, n (%) | P-value | Positive, n (%) | P-value | Positive, n (%) | P-value |
| Sex | 0.3883 | 0.7376 | 0.7935 | 0.4272 | ||||
| Male | 137 (34.0) | 203 (50.4) | 225 (56.3) | 163 (40.5) | ||||
| Female | 94 (30.9) | 157 (51.6) | 174 (57.2) | 132 (43.4) | ||||
| Age, years | 0.8618 | 0.0790 | 0.8739 | 0.4837 | ||||
| <65 | 127 (32.4) | 188 (48.0) | 220 (56.4) | 159 (40.6) | ||||
| ≥65 | 104 (33.0) | 172 (54.6) | 179 (57.0) | 136 (43.2) | ||||
| Grade | 0.2914 | 0.2749 | 0.0160 | 0.7015 | ||||
| 1 | 134 (33.7) | 196 (49.3) | 240 (60.5) | 171 (43.0) | ||||
| 2 | 78 (29.8) | 143 (54.6) | 141 (53.8) | 104 (39.7) | ||||
| 3+4 | 19 (40.4) | 21 (44.7) | 18 (40.0) | 20 (42.6) | ||||
| Tumor size, cm | 0.6494 | 0.6620 | 0.2653 | 0.0537 | ||||
| <5 | 153 (33.3) | 237 (51.5) | 266 (58.2) | 204 (44.4) | ||||
| ≥5 | 78 (31.6) | 123 (49.8) | 133 (53.9) | 91 (36.8) | ||||
| Vascular invasion | 0.0184 | 0.0334 | 0.6958 | 0.7546 | ||||
| Negative | 208 (34.4%) | 42 (41.2) | 343 (57.0) | 44 (43.1) | ||||
| Positive | 23 (22.6%) | 318 (52.6) | 56 (54.9) | 251 (41.5) | ||||
| TNM stage | 0.0215 | 0.3616 | 0.5857 | 0.6859 | ||||
| 0+I | 38 (40.0) | 51 (53.7) | 51 (53.7) | 36 (37.9) | ||||
| II | 106 (35.9) | 157 (53.2) | 173 (58.8) | 123 (41.7) | ||||
| III+IV | 87 (27.4) | 152 (48.0) | 175 (55.6) | 136 (42.9) | ||||
COUP-TFII, chicken ovalbumin upstream promoter-transcription factor II; LXR, liver X receptor; RXRα, retinoid X receptor α; SREBP-1c, sterol regulatory element binding protein-1c.